I believe Susan Bayh was taken to Georgetown under emergency circumstances, surgery performed, and tumor was not saved properly. No DCVax-L could be made without tumor.
NWBO's blinded data suggests much better 3 year survival than 17% though the 17% mentioned might include all patients vs those selected for the L trial which are probably a middle group of enrolled patients that sits a little above an all comers median. As others have already mentioned, it appears Susan was not in position at the time of her surgery to get her tumor tissue preserved properly for treatment with L. Best wishes.